AR096045A1 - Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco - Google Patents

Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco

Info

Publication number
AR096045A1
AR096045A1 ARP140101650A ARP140101650A AR096045A1 AR 096045 A1 AR096045 A1 AR 096045A1 AR P140101650 A ARP140101650 A AR P140101650A AR P140101650 A ARP140101650 A AR P140101650A AR 096045 A1 AR096045 A1 AR 096045A1
Authority
AR
Argentina
Prior art keywords
pharmaceutical composition
dry eye
eye syndrome
formulation
prevent
Prior art date
Application number
ARP140101650A
Other languages
English (en)
Inventor
Woo Lee Sung
Ju Choi Sung
Seok Park Ki
Jong Shin Hee
Hwan Cho Eui
Bae Yoon Jong
Tae Nam Ho
Original Assignee
Samjin Pharm Co Ltd
Astech Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Samjin Pharm Co Ltd, Astech Co Ltd filed Critical Samjin Pharm Co Ltd
Publication of AR096045A1 publication Critical patent/AR096045A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composición farmacéutica oral para prevenir o tratar el síndrome de ojo seco, la cual comprende rebamipida o una prodroga de la misma, o una sal farmacéuticamente aceptable de la misma, como un ingrediente activo. Los compuestos pueden tratar el síndrome de ojo seco a través de la vía oral, y pueden ser entonces empleados de manera segura y conveniente en comparación con las gotas para ojos convencionales. Reivindicación 2: La composición farmacéutica de la reivindicación 1, caracterizada porque la prodroga se selecciona a partir del grupo que consiste en los compuestos de fórmula química (1) a (6). Reivindicación 10: La formulación farmacéutica de la reivindicación 9, caracterizada porque está en la forma de polvo, gránulos, comprimidos, suspensiones, emulsiones, jarabes, aerosoles, o cápsulas de gelatina blandas o duras.
ARP140101650A 2013-04-18 2014-04-21 Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco AR096045A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR1020130043141A KR101692578B1 (ko) 2013-04-18 2013-04-18 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물

Publications (1)

Publication Number Publication Date
AR096045A1 true AR096045A1 (es) 2015-12-02

Family

ID=51731606

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP140101650A AR096045A1 (es) 2013-04-18 2014-04-21 Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco

Country Status (18)

Country Link
US (1) US11712414B2 (es)
EP (1) EP2987491B1 (es)
JP (1) JP6249194B2 (es)
KR (1) KR101692578B1 (es)
CN (1) CN105142637B (es)
AR (1) AR096045A1 (es)
AU (1) AU2014254621B2 (es)
BR (1) BR112015026332B1 (es)
CA (1) CA2909806C (es)
ES (1) ES2813649T3 (es)
IL (1) IL242143B (es)
MX (1) MX2015014672A (es)
MY (1) MY183526A (es)
PH (1) PH12015502406A1 (es)
RU (1) RU2632107C2 (es)
SA (1) SA114350449B1 (es)
TW (1) TWI535441B (es)
WO (1) WO2014171748A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물
KR101764377B1 (ko) 2017-03-22 2017-08-02 주식회사 메디컬오 천연 추출물을 포함하는 안구건조증 치료제
CN109134533B (zh) * 2017-06-27 2020-08-11 维眸生物科技（上海）有限公司 一种含磷化合物及其制备和应用
WO2019036050A1 (en) * 2017-08-18 2019-02-21 Schepens Eye Research Institute COMPOSITIONS FOR TREATING DRY EYE AND METHODS OF USE
KR101840256B1 (ko) * 2017-09-21 2018-03-21 대우제약 주식회사 레바미피드를 함유하는 새로운 안구건조증 치료용 점안 조성물 및 이의 가용화 및 안정화 방법
KR101923519B1 (ko) * 2018-06-26 2019-02-27 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR20200019451A (ko) 2018-08-14 2020-02-24 대우제약 주식회사 레바미피드를 함유하는 안구 건조증 치료용 수용성 다회용 점안제 조성물 및 이의 가용화 및 안정화 방법
KR102190019B1 (ko) * 2018-10-23 2020-12-15 삼진제약주식회사 쇼그렌 증후군 예방 또는 치료용 조성물
CN114404379B (zh) * 2022-01-29 2024-01-26 杭州沐源生物医药科技有限公司 一种瑞巴派特缓释片及其制备方法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3093661B2 (ja) 1995-10-12 2000-10-03 大塚製薬株式会社 眼疾患治療剤
AR004214A1 (es) 1995-10-12 1998-11-04 Otsuka Pharma Co Ltd Una preparación de gotas oftálmicas para la cura de enfermedades oftálmicas
TWI363626B (en) 2004-11-15 2012-05-11 Otsuka Pharma Co Ltd Aqueous ophthalmic suspension of crystalline rebamipide
NZ556627A (en) * 2005-02-22 2010-09-30 Pfizer Oxyindole derivatives as 5HT4 receptor agonists
ES2389566T3 (es) * 2005-05-17 2012-10-29 Santen Pharmaceutical Co., Ltd. Agente preventivo o terapéutico para tratar un transtorno de la córnea y la conjuntiva
WO2008074853A1 (en) * 2006-12-21 2008-06-26 Novartis Ag Ophthalmic rebamipide solution
US20090131303A1 (en) * 2007-11-16 2009-05-21 Bor-Shyue Hong Methods and compositions for treating dry eye
CN102065893A (zh) * 2008-04-15 2011-05-18 萨可德公司 Lfa-1拮抗剂向胃肠系统的递送
US8080562B2 (en) * 2008-04-15 2011-12-20 Sarcode Bioscience Inc. Crystalline pharmaceutical and methods of preparation and use thereof
JP2009301866A (ja) 2008-06-13 2009-12-24 Panasonic Corp プラズマディスプレイパネルの製造方法
RU2538694C2 (ru) 2008-06-19 2015-01-10 Оцука Фармасьютикал Ко., Лтд. Фармацевтическая композиция
SA113340675B1 (ar) * 2012-06-26 2015-08-16 استيش. كو.، ليمتد أدوية ريباميبايد تحضيرية جديدة، طريقة تحضيرها واستخدامها
KR101692578B1 (ko) * 2013-04-18 2017-01-03 삼진제약주식회사 레바미피드 또는 이의 전구체를 포함하는 안구건조증의 예방 또는 치료를 위한 경구용 약제학적 조성물

Also Published As

Publication number Publication date
WO2014171748A1 (ko) 2014-10-23
BR112015026332A2 (pt) 2017-07-25
EP2987491B1 (en) 2020-06-03
MY183526A (en) 2021-02-24
CA2909806A1 (en) 2014-10-23
PH12015502406A1 (en) 2016-02-22
SA114350449B1 (ar) 2016-05-08
EP2987491A4 (en) 2016-12-28
CN105142637A (zh) 2015-12-09
CN105142637B (zh) 2021-08-17
JP6249194B2 (ja) 2017-12-20
RU2632107C2 (ru) 2017-10-02
TWI535441B (zh) 2016-06-01
JP2016520566A (ja) 2016-07-14
MX2015014672A (es) 2016-02-19
US11712414B2 (en) 2023-08-01
US20160081922A1 (en) 2016-03-24
TW201442710A (zh) 2014-11-16
CA2909806C (en) 2020-04-21
RU2015146417A (ru) 2017-05-24
KR101692578B1 (ko) 2017-01-03
AU2014254621B2 (en) 2017-06-08
EP2987491A1 (en) 2016-02-24
KR20140125230A (ko) 2014-10-28
AU2014254621A1 (en) 2015-11-19
IL242143B (en) 2021-03-25
ES2813649T3 (es) 2021-03-24
BR112015026332B1 (pt) 2022-05-03

Similar Documents

Publication Publication Date Title
AR096045A1 (es) Composición farmacéutica y formulación para prevenir o tratar el síndrome de ojo seco
CY1122730T1 (el) 1,2,4-τριαζολες ως διαμορφωτες πυρηνικης μεταφορας και χρησεις αυτων
DOP2018000273A (es) Compuestos químicos
UY35684A (es) Formulación de inhibidores de la tirosina quinasa de bazo (syk)
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR090456A1 (es) Combinaciones farmaceuticas que comprenden un analogo de tionucleotidos
EA201692249A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
NI201600058A (es) Compuestos derivados de piridilo bicíclicos fusionados a anillo como inhibidores de fgfr4
EA201790202A1 (ru) Фталазиноны и изохинолиноны в качестве ингибиторов rock
EA201891063A1 (ru) Производные дигидроимидазопиразинона, применимые в лечении рака
WO2016011390A8 (en) Irak4 inhibiting agents
AR093244A1 (es) Compuestos de benceno sustituidos utilizables en el tratamiento de trastornos mediados por ezh2
EA201691803A1 (ru) Ингибиторы калликреина плазмы человека
NZ728392A (en) High dosage strength tablets of rucaparib
WO2016044641A3 (en) Carm1 inhibitors and uses thereof
CL2015001279A1 (es) Compuestos derivados de piridina, inhibidores del transportador de uratos urat 1; composicion farmaceutica que los comprende; uso para el tratamiento o prevencion de enfermedades tales como gota, hiperuricemia, hipertensión, enfermedades renales, entre otras.
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CU20160192A7 (es) Derivados de indano e indolina útiles como activadores de la guanilato ciclasa soluble
PE20142258A1 (es) Compuesto heterociclico nitrogenado
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
EA201692265A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
WO2017089390A8 (en) Janus kinases inhibitors, compositions thereof and use thereof
EA201891267A1 (ru) Фармацевтическая композиция, содержащая действенный ингибитор urat1
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
RU2017116740A (ru) Комбинации для лечения рассеянного склероза

Legal Events

Date Code Title Description
FB Suspension of granting procedure